American Academy of Ophthalmology launches registry

Laura Pedulli | | Health Exec | Economics

The American Academy of Ophthalmology launched the first comprehensive centralized data repository specifically focused on eye diseases and conditions.

The Intelligent Research in Sight (IRIS) Registry is a data repository and reporting tool that aggregates patient data from EHRs and performs statistical analysis that enables ophthalmologists to improve patient care, reduce the cost and enhance the speed of some large clinical trials, assist in monitoring resource utilization, comply with federal payment programs and enhance quality and practice efficiency, according to the academy.

To date, 2,300 physicians in 47 states nationwide are participating in the IRIS Registry, having signed up during a limited rollout, which began in 2013. The ophthalmology registry contains more than 5 million patient records and is expected to ultimately house more than 20 million in two years.

More information is available here. 

Laura Pedulli

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.